Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Zura Bio Limited. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Zura Bio Limited (ZURA) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of Zura Bio Limited (NASDAQ: ZURA).
On November 9, 2026, Zura Bio Limited announced that its Phase 2 TibuSHIELD trial of tibulizumab did not meet its primary endpoint. Following this news, Zura’s stock price fell $2.85 per share, or approximately 69.7%, to close at $1.24 per share on November 9, 2026.
What Potential Securities Violations Is BG&G Investigating?
- Whether Zura Bio Limited and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- Whether Zura Bio Limited failed to disclose material adverse information that would have been significant to a reasonable investor.
- Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
What Should Zura Bio Limited (ZURA) Investors Do?
If you purchased or acquired ZURA securities and suffered a loss, you may have a claim.
Contact BG&G to share relevant facts or information about your purchase.
There is no cost or obligation — our firm works exclusively on a contingency fee basis.
You do not need to have sold your shares to contact us.
How Is Zura Bio Limited (NASDAQ: ZURA) Stock Trading Today?
Interactive chart showing the weekly share price history of NASDAQ:ZURA (NASDAQ:ZURA).
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”